The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy

  • STATUS
    Recruiting
  • participants needed
    12
  • sponsor
    Nagoya University
Send
Updated on 19 February 2024
See if I qualify

Summary

The purpose of this study is to evaluate the safety and the tolerability of CL2020 cells in hypoxic ischemic encephalopathy neonates with hypothermia therapy. In addition, we will evaluate the efficacy of CL2020 cells for infant development.

Details
Condition Hypoxic Brain Damage
Age 1years or below
Treatment CL2020 cells
Clinical Study IdentifierNCT04261335
SponsorNagoya University
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

At least 36 weeks gestation, and either one of the following criteria (i.-iii.) i. Apgar score 5 at 10 minutes ii. Continued resuscitation for at least 10 minutes iii. pH <7.0 or base deficit 16 mmol/L in any blood sample obtained within 60 min of birth
Moderate or severe encephalopathy by a Sarnat criteria
Undergone therapeutic hypothermia started before six hours of birth, and done for 72 hours continuously
Birth weight 1,800 g
Heart rate 100/min, and SpO2 90 %
Able to provide voluntary written consent after receiving adequate information about the study (consent will be obtained from an acceptable representative)

Exclusion Criteria

Suspected or confirmed severe congenital abnormalities or chromosomal anomaly
Planned to undergo surgery or radiation therapy
Scheduled to take systemic corticosteroids treatment for over five days
Blood glucose 200 mg/dL
Participation in another clinical study (not exclude patients in observational studies)
Suspected or confirmed active and severe infection
Positive for HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody or syphilis serum reaction
History of severe hypersensitivity or anaphylactic reaction
Severe complications
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.